Navigation Links
SeqWright to Invest in LaserGen's Novel Lightning Terminators(TM)
Date:4/8/2009

HOUSTON, April 8 /PRNewswire/ -- LaserGen, Inc., a DNA sequencing technology company, announced a definitive agreement in which SeqWright Inc. will make an equity investment in the company. Prompting its decision was LaserGen's recently revealed plans to commercialize its novel reversible terminator chemistry, Lightning Terminators(TM), for next-generation sequencing applications. The company anticipates bringing its chemistry as reagent kits to the market as early as 2010, by forming strategic partnerships with existing next-generation instrument manufacturers. SeqWright's investment and next-generation sequencing expertise are expected to facilitate LaserGen's effort in achieving that goal. Financial terms of the transaction were not disclosed.

The superior kinetics and natural DNA restoration of Lightning Terminators(TM) inform the promise of increased speed, throughput, and read-length, while lowering cost. These benefits are achieved through LaserGen's nucleotide chemistry by attaching a special terminating group directly to the base, freeing up the critical 3'-hydroxyl group. These Lightning Terminators(TM) exhibit excellent enzymatic properties with commercially available DNA polymerases. In kinetic terms, Lightning Terminators(TM) are more efficient than natural nucleotides, a measure of how fast they are added by and how well they bind to DNA polymerase. Simply stated, Lightning Terminators(TM) are better than nature. All reversible terminators required a cleavage step to remove the terminating and fluorescent dye groups. Upon cleavage, however, Lightning Terminators(TM) restore the incorporated nucleotide back to its natural state. This distinguishes the LaserGen chemistry from other reversible terminators, which leave accumulating molecular scars as the DNA strand propagates.

The decision to invest in LaserGen represents SeqWright's ongoing initiative to support the development of and build upon its previous investments in next-generation sequencing technologies. As a large-scale provider of DNA sequencing services, SeqWright is ideally suited to invest in next-generation technologies by providing equity investment, testing and validation. "We are very pleased to support LaserGen in their efforts," says Dr. Fei Lu, M.D., CEO of SeqWright Inc., "to advance the state of DNA sequencing, and we are excited about the savings in both, time and cost, which we expect their technologies to generate."

About LaserGen

LaserGen, Inc. is an early-stage nucleic acids chemistry company, founded in 2002. The company has been funded through NIH-sponsored small business and research grants to develop a variety of innovative technologies for next-generation sequencing applications. The SeqWright agreement marks LaserGen's transition from bench discoveries to market-ready technologies. Information about LaserGen, Inc. is available at www.lasergen.com

About SeqWright

SeqWright Inc. is a commercial provider of genomic analysis and molecular biology services. SeqWright has more than 15 years of experience specializing in state-of-the-art molecular biology and genomic services within a highly regulated GLP/CLIA environment. For additional information about SeqWright, please visit www.seqwright.com.


'/>"/>
SOURCE SeqWright Inc.; LaserGen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. California Grants SeqWright License to Operate as a Clinical Laboratory
2. SeqWright Expands Next Generation Lineup with the Addition of 454s GS FLX(TM) System
3. SeqWright Unveils ABI SOLiD(TM) Next Generation Genetic Analysis System
4. Voler Systems Continues Investments and Expands Services
5. Pharmaxis Investor Conference Call
6. Senetek PLC Announces New Investor Communication Hotline
7. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citi Conference
9. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
10. Stallergenes : Investor Meeting: Webcast is Available
11. Accera, Inc. to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... ... gene in its endogenous context, enabling overexpression experiments and avoiding the use of ... small RNA guides is transformative for performing systematic gain-of-function studies. , This ...
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/11/2017)... Tampa Bay, Florida (PRWEB) , ... October 11, ... ... Food and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its ... antibody (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Club. The event entitled “Stem Cells and Their Regenerative Powers,” was ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
Breaking Biology News(10 mins):